Abstract

The features of the engraftment in 26 patients allografted using reduced-intensity conditioning regimen (8 with chronic myelogenous leukemia, 6 with acute myelogenous leukemia, 9 with acute lymphoblastic leukemia, 1 with hybrid acute leukemia, 1 with myelodysplasia and 1 with thalassemia major) were analyzed. Patients received a median of 10 × 108/Kg mononuclear cells (range 1.6 to 22.9), and a median of 4.2 × 106/Kg CD34 cells (range 0.3 to 14). There was a linear correlation between the number of infused mononuclear cells (MNC) and that of CD34 cells (r = 0.78, p = 0.002). Three patients (11%) failed to engraft; in those who engrafted, the median time to achieve >500 granulocytes was 11 days (range 10 to 22), and the median time to achieve >10 000 platelets was 12 days (range 10 to 41). The three patients who failed to engraft received less than 5 × 108/Kg MNC (1.6,4.6 and 4.9) and less than 0.5 × 106/Kg CD34; however, five of eight patients who received less than 5 × 108/Kg MNC still engrafted succesfully. On the other hand, all the patients who received less than 0.5 × 106/Kg CD34 cells failed to engraft. Within the group of patients who engrafted, it was found that those who received more than 7 × 106/Kg CD34+ cells tended to earlier recover > 20 × 109/L platelets (p = 0.02), and > 0.5 × 109/L neutrophils (p = 0.06) before day 15, than those who received less than 7 × 106/Kg CD34+ cells. No such association could be established between the number of MNC and the time for recovery. In these patients allografted using reduced-intensity conditioning regimens, the target doses of hematopoietic cell used were similar to those described for conventional allografts: The number of CD34 infused cells was significantly related to the possibility of failure to engraft and to the recovery rate of the hemopoiesis.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.